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1. introduction 
The acceleration of the entry of glucose into 
muscle which occurs upon contraction depends on 
the presence of small concentrations of insulin [I]. 
This suggests hat the ‘muscle activity factor’ which is 
released from exercising muscle [2] exhibits its action 
on glucose utilization by improving insulin sensitivity 
of muscle tissue. During the last few years appreciable 
experimental evidence has been accumulated suggest- 
ing that kinins might represent the still unidentified 
humoral factor. Thus, it was shown in studies on the 
human forearm that the increase of glucose uptake 
during work load [3] or hypoxia [4] was completely 
abolished after treatment with a protease inhibitor 
which prevents the formation of kinins from kininogen. 
Thii effect could be overcome by the administration 
of synthetic bradykinin. Moreover, bradykinin 
exhibited insulin-like activity on glucose uptake also 
in the resting forearm muscle in the normal [S] and 
in the maturity onset diabetic patient 161. Prom these 
and further studies pointing to an involvement of 
kinins in the physiological action of insulin on 
muscular glucose uptake [7,8] it seemed of interest 
to ~vestigate the possibility whether kinins might 
also be useful therapeutically by improving the eff- 
ciency of insuliu in the treatment of diabetes. 
2. Materials and methods 
Male Sprague Dawley rats (I 70-200 g) fed ad 
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libitum on a chow diet were used. Diabetes was 
induced by intravenous injection of 10 mg alloxan/ 
100 g body wt (Merck AG, Darmstadt). After 24 h, 
treatment was started applying 3 U Depot Insulin 
Hoechst CS (Hoechst AG, Frankfurt) subcutaneously 
(SC.) at 12 h intervals for 3 days. Thereafter, before 
injection of insulin, body weights were registered and 
blood samples taken from the tail vein without 
anaesthesia for enzymatic determination of glucose 
at 8 a.m. In one group, the animals received no further 
insulin but were treated every 12 h for 3 days by S.C. 
injection of synthetic bradykinin (Sandoz AC, 
Ntirnberg) at increasing doses as indicated in table 1 
(group A). Another group received further insulin 
therapy continued for 6 days as indicated in table 1 
(group B). Group C in table 1 was treated by a com- 
b~ation of 3 U insulin plus varying amounts of 
bradykinin mixed immediatedly before use and 
injected every 12 h. Thereby, daily glucose concen- 
trations were registered in both groups as indicated 
in fig.1. Under these c~cu~tances apportion of 
bradykinin was stopped in one group and started in 
the other as indicated in fig.1. Group D received the 
two drugs not mixed in a syringe but injected sepa- 
rately at two different sites. In further experiments 
insulin therapy was combined with S.C. application of 
papaverine at 2 doses (2 X 0.75 mg/day and 
2 X 5.25 mg/day; Dept. Pharmacol., Schwabing 
Hospital, Munch) and of eledoisin (2 X 5 lg/day and 
2 X 7.5 pg/day; Serva AG, Heidelberg). After 3 days 
of treatment blood glucose was determined at 8 a.m. 
Another set of experiments was designed to study 
the effect of combined ~su~-bradyk~in treatment 
also on the plasma levels of free fatty acids, fl-hydroxy- 
butyrate and alanine and on liver glycogen. For that 
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purpose the rats after the treatment indicated in 
table 2 were anaesthetized with phenobarbitai sodium 
(Nembutal~, Abott, Belgium, 50 mg/kg intraperito- 
neally) and their arterial blood taken from the aorta 
for analyses. Procedures and precision of the tests 
have been given in [9]. After blood sampling the livers 
were rapidly freeze clamped and glycogen was deter- 
mined enzymatical~y according to [lo]. Standard 
statistical methods were employed using Student’s 
t-test for paired and unpaired samples when appli- 
cable [ 111. 
3. Results 
The data obtained under bradykinin without 
insulin, under insulin at different doses (2 X.3 U, 
2 X 4 U, 2 X 5 U) and insulin (2 X 3 U) mixed with 
bradyk~in at different doses (2 X 2.5 pg, 2 X 5 pg, 
2 X 10 gg) and under insulin (2 X 3 U) and brady- 
kinin (2 X 20 ,ug) applied separately are indicated in 
table 1. The effects of 2 X 3 U insulin mixed with 
2 X 10 pg bradykinin on carbohydrate-, free fatty 
acid-, ketone- and amino acid metabolism are given 
in table 2. There was no increase of the radio- 
immunologically measurable insulin concentration 
(insulin, 2 -36 f 0.93 PUfml; insulin + brady~nin , 
0.65 -?r 0.21 @U/ml), but a reduction which cannot 
be explained so far. The time course of blood glucose 
under the influence of insulin and of insulin mixed 
with bradykinin is indicated in fig.1. Addition of 
papaverine and of eledoisine at different doses 
ex~bited no effect on glucose concentration: 
Insulin (2 X 3 U) at 2 1 .O * 0.9 mmoljl; 
Insulin (2 X 3 U) t papaverine (2 X 0.75 mg) at 
20.96 + 0.71 mmol/l; 
Insulin (2 X 3 U) t papaverine (2 X 5.25 mg) at 
2 1.8 + 0.6 mmoljl; 
Insulin (2 X 3 U) t eledoisin (2 X 2.5 pg) at 
19.01 * 2.08 mmol/l; 
Insulin (2 X 3 U) t eledoisin (2 X 7.5 pg) at 
22.03 + 0.95 mmol/l. 
4. Discussion 
Addition of bradykinin to insulin revealed ose- 
dependent improvement of diabetes concerning not 
only carbohydrate but also fat and amino acid metab- 
olism (tables 1,2). It was manifest within 12 h and 
Table 1 
Effect of bradykinin and insulin on carbohydrate-metabolism 
Group Experiment 
Insulin (U/24 h) Bradykinm @g/24 h) 
Treatment Ha 
(days) 
Blood glucose (mmol/l) 
Basalb After treatment 
A 2x 10 3 6 21.2 f 3.2 36.8 f l.lc 
- 2x 80 3 5 18.0 * 1.7 30.6 + 4.4c 
- 2X 160 3 5 20.7 f 1.6 38.5 it l.gc 
2 x 200 3 5 20.7 + 2.3 34.6 + 1.8c 
B 2x3 - 6 44 20.1 * 1.4 22.5 f 1.1 
2X.5 - 6 18 21.0 + 2.0 16.2 f 1.6c3d*e 
2X6 6 15 24.9 f 2.0 1.6 f 1.7C*d 
Cf 2x3 2x 2.5 6 7 20.7 f 3.0 13.6 t 2.6Cvd 
2x3 2x 5 6 6 21.0 f 2.1 6.1 + 1 Ocsd 
2x3 2x 10 6 42 20.8 f 1.5 6.3 f 0.5C>d 
Dg 2x3 2x 20 6 13 21.0 f 1.7 14.2 f 2.0cvd 
Mean f SEM: aNumber of rats; h31 oo d sugar after the first Zday insulin treatment after alloxan; CSignificantly different to basal 
@ < 0.05, paired r-test); dSigniflcantly different to 6 W ins@in/day @ < 0.05, unpaired f-test); eSignificantly different to 6 U 
insulin + 10 Mg brady~~/day Q.J < 0.05, unpaired t-test); fDrugs a~~istered in mixture; gDrugs administered separately 
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Table 2 
Improvement of the diabetic carbohydrate-, fat-, ketone- and ammo acid metabolism 
by bradykinin 
N Insulina N Insulin + Bradykininb P 
c1ucosec 20 14.3 f 1.7 12 5.9 + 0.6 <0.0005 
Free fatty acidsC 20 0.39 + 0.04 9 0.23 * 0.04 CO.01 
P-HydroxybutyrateC 18 0.45 + 0.06 12 0.29 + 0.05 CO.05 
AlanineC 19 0.35 f 0.02 12 0.29 f 
Liver glycogend 
0.02 <o.os 
17 8.7 + 0.9 10 4.5 f 0.6 <0.0025 
Liver weighte 19 10.6 f 0.3 11 9.2 + 0.3 <0.0025 
Increase of 
body weightf 
20 130 * 1 18 138 +l 
Mean f SEM: a2 X 3 U/24 h for 6 days; b3 U insulin mixed with 10 fig twice daily for 
6 days; CArterial concentration (mmol/l); dg/lOO g wet wt; eg wet wt; f% 
disappeared in 24-36 h after the end of treatment 
(fig.1). The doses used were far beyond those known 
to cause lowering of blood pressure (reviewed [ 121). 
Comparing the dose with that of insulin it turned out 
to be almost equimolar. Since bradykinin exhibited 
no increased secretion of insulin (see section 3) four 
possible ways were left how it might have worked: 
(i) By increased mobilization of insulin via accelerated 
subcutaneous blood flow [ 121 and/or via improved 
vascular permeability [ 121; 
l . b 
OJ 
6 7 8 9 IO 11 12 dayC 
Fig.1. Effect of bradykinin (BK) on blood glucose in the 
alloxandiabetic, insulin-treated rat. Mean f SEM of 12 animals 
in each group under insulin (2 X 3 U) (e,u) and insulin plus 
BK (2 X 3 U plus 2 X 5 rcg) (qo). (a) 12 h after start with 
BK; (b) 36 h after stop with BK; (c) days of in&in treatment. 
(*) significantly different to preceding value @ < 0.01, 
paired t-test). 
(ii) By reduction of local insulin degradation; 
(iii) By an alteration of insulin’s structure improving 
its physiological action; 
(iv) By faster glucose uptake into muscle tissue as 
found [3--S]. 
The first and second notion were not very probable 
since papaverine and eledoisin which exhibit identical 
action on blood flow [ 121 and vascular permeability 
[ 121 and similar chemical properties [ 121 did not 
affect metabolism (see section 3). Concerning the 
third possibility, there was no evidence from the 
literature that a peptide might alter insulin’s structure 
revealing increased physiological action of the hor- 
mone, although the finding that bradykinin was 
beginning to work at equimolar doses pointed to that 
view. Furthermore, the first and second notion were 
not very likely since kinins were also working when 
applied separately (table 1). 
The last mechanism seems to be the most probable 
although it is difficult to imagine how kinins which 
are rapidly degraded [ 131 might entirely get to muscle 
tissue. However, considering that insulin works as an 
important kininase inhibitor [ 141, bradykinin was 
probably prevented from degradation if applied 
together with the hormone. This notion was also under- 
lined by its smaller effect when applied separately 
from insulin (table 1). Since plasma insulin rises con- 
siderably after its subcutaneous application, kinins 
would also be preserved on their way to muscle tissue. 
Finally, these data also fit into the notion that these 
tissue hormones are involved in the control of sub- 
strate metabolism by improving insulin sensitivity. 
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